Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Fig 1 - by Sara E. Harrod (14129292)

Two different <i>Hmr</i> mutations interfere differently with HMR interactome and HMR complex formation. by Andrea Lukacs (3752956)

DataSheet_1_Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.xlsx by Boram Lee (549836)

“…The genes most frequently altered (> 20%) were (in decreasing order of frequency) CDKN2A, PIM1, CD79B, TP53, MYD88, MYC, BTG2, BTG1, CDKN2B, DTX1, CD58, ETV6, and IRF4. …”

Decreased presence of tubulin-GFP at axonal MTs in a pulse chase experiment suggests changes in MT replenishment with age. by Pilar Okenve-Ramos (18150546)

IpaH9.8 mutants display decreased activity to degrade the GBPs. by Chenggong Ji (6858425)

Table 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx by Lili Zhou (265076)

“…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”

Deletion of murine <i>Rhoh</i> leads to de-repression of <i>Bcl-6</i> via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma by Hiroto Horiguchi (3215001)

“…RHOH was initially identified as a translocation partner with BCL-6 in non-Hodgkin lymphoma (NHL), and aberrant somatic hypermutation (SHM) in the 5ʹ untranslated region of the RHOH gene has also been detected in Diffuse Large B-Cell Lymphoma (DLBCL). Recent data suggest a correlation between RhoH expression and disease progression in Acute Myeloid Leukaemia (AML). …”

Fig 1 - by Gláucia Helena Fernandes Seixas (5866511)

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. by Peiqi Yin (6533747)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Foldases and holdases each decrease the level of unfolded protein. by Adam MR de Graff (9767829)

Decreased UFA/SFA ratio induces cytosolic chaperones. by Dongyeop Lee (108880)

“…The expression changes were not statistically significant because of large variations. (<b>F</b>) A targeted RNAi screen against metabolic genes using <i>hsp-16</i>.…”

Probability of survival for snails in treatment groups of 0.38 ppt, 1.9 ppt, 3.8 ppt, 5.7 ppt salinity treatments. by Ao Yu (1348512)

Silkworm ovaries and ovarioles infected by <i>N</i>. <i>bombycis</i>. by Chunxia Wang (766713)

Subjects:

The infection of follicle and nurse cells by <i>N</i>. <i>bombycis</i>. by Chunxia Wang (766713)

Subjects:

Salivary IgA specific to SARS-CoV-2 RBD in N = 40 individuals prior first (V1), three weeks after first (V2) and to weeks after second vaccination (P1) in comparison with COVID-19... by Olaf Nickel (9524791)

Subjects:

Egg mass output for uninfected snails in treatment groups 0.38 ppt, 1.9 ppt, 3.8 ppt, and 5.7 ppt. by Ao Yu (1348512)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects: